BMB Reports : eISSN 1976-670X

Cited by CrossRef (15)

  1. Katharina Eva Ruppel, Stephan Fricke, Ulrike Köhl, Dominik Schmiedel. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Front. Immunol. 2022;13
    https://doi.org/10.3389/fimmu.2022.822298
  2. Yingyan Yu. Multi-target combinatory strategy to overcome tumor immune escape. Front. Med. 2022;16:208
    https://doi.org/10.1007/s11684-022-0922-5
  3. Dan Qiu, Xiaxin Liu, Wandi Wang, Xuan Jiang, Xiaofang Wu, Jiamian Zheng, Kai Zhou, Xueting Kong, Xiuli Wu, Zhenyi Jin. TIGIT axis: novel immune checkpoints in anti-leukemia immunity. Clin Exp Med 2022
    https://doi.org/10.1007/s10238-022-00817-0
  4. Chang Xu, Hanji Fang, Yun Gu, Kuan Yu, Jieti Wang, Chao Lin, Heng Zhang, He Li, Hongyong He, Hao Liu, Ruochen Li. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer . Cancer Science 2022
    https://doi.org/10.1111/cas.15537
  5. Xinqiang Li, Shipeng Li, Bin Wu, Qingguo Xu, Dahong Teng, Tongwang Yang, Yandong Sun, Yang Zhao, Tianxiang Li, Dan Liu, Shuang Yang, Weihua Gong, Jinzhen Cai. Landscape of Immune Cells Heterogeneity in Liver Transplantation by Single-Cell RNA Sequencing Analysis. Front. Immunol. 2022;13
    https://doi.org/10.3389/fimmu.2022.890019
  6. Maria V. Deligiorgi, Dimitrios T. Trafalis. The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum. JCM 2022;11:3417
    https://doi.org/10.3390/jcm11123417
  7. Michael Kuske, Maximilian Haist, Thomas Jung, Stephan Grabbe, Matthias Bros. Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. Cancers 2022;14:1710
    https://doi.org/10.3390/cancers14071710
  8. Si‐Jia Zhao, Kahindo P. Muyayalo, Jing Luo, Donghui Huang, Gil Mor, Ai‐Hua Liao. Next generation of immune checkpoint molecules in maternal‐fetal immunity*. Immunological Reviews 2022;308:40
    https://doi.org/10.1111/imr.13073
  9. Fengqing Wu, Huan Yang, Xiao Xu, Conglin Ren, Yang Zheng, Helou Zhang, Bingbing Cai, Rui Qiu, Weifan Ren, Renfu Quan, Hannes Stockinger. CD96 Downregulation Promotes the Immune Response of CD4 T Cells and Associates with Ankylosing Spondylitis. BioMed Research International 2022;2022:1
    https://doi.org/10.1155/2022/3946754
  10. Alice Indini, Daniela Massi, Matteo Pirro, Fausto Roila, Francesco Grossi, Amirhossein Sahebkar, Nicole Glodde, Tobias Bald, Mario Mandalà. Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. Seminars in Cancer Biology 2022;86:477
    https://doi.org/10.1016/j.semcancer.2022.06.005
  11. Peter S. Lee, Bryant Chau, Ishita Barman, Christine Bee, Aarti Jashnani, Jason M. Hogan, Barbara Aguilar, Gavin Dollinger, Arvind Rajpal, Pavel Strop. Antibody blockade of CD96 by distinct molecular mechanisms. mAbs 2021;13
    https://doi.org/10.1080/19420862.2021.1979800
  12. Manuel Weber, Rainer Lutz, Manuel Olmos, Jacek Glajzer, Christoph Baran, Christopher-Philipp Nobis, Tobias Möst, Markus Eckstein, Marco Kesting, Jutta Ries. Beyond PD-L1—Identification of Further Potential Therapeutic Targets in Oral Cancer. Cancers 2022;14:1812
    https://doi.org/10.3390/cancers14071812
  13. Qiaxuan Li, Daipeng Xie, Lintong Yao, Hongrui Qiu, Peimeng You, Jialong Deng, Congsen Li, Weijie Zhan, Maotao Weng, Shaowei Wu, Fasheng Li, Yubo Zhou, Fanjun Zeng, Yong Zheng, Haiyu Zhou. Combining autophagy and immune characterizations to predict prognosis and therapeutic response in lung adenocarcinoma. Front. Immunol. 2022;13
    https://doi.org/10.3389/fimmu.2022.944378
  14. Cristina Capuano, Chiara Pighi, Simone Battella, Davide De Federicis, Ricciarda Galandrini, Gabriella Palmieri. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. Cancers 2021;13:2500
    https://doi.org/10.3390/cancers13102500
  15. Xia Zhou, Sohail Khan, Dabing Huang, Lu Li. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. Front. Immunol. 2022;13
    https://doi.org/10.3389/fimmu.2022.938470